Phase 2 N=124 Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer
Breast Cancer · Stage IV Breast Cancer
Primary: Progression-free Survival by CYP2D6 Status in 2 Categories — 12.9; 6.9 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=2,105 Flu2Text: Text Message Reminders for 2nd Dose of Influenza Vaccine
Influenza · Vaccination
Primary: Percentage of Participants Who Receive Influenza Vaccination by April 30 Each Year — 875; 843 Participants
Phase 1 N=20 Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers
HIV Infections
Primary: Safety and Tolerability of PRO 140 — 4; 4; 0; 4 number of subjects reporting AEs
Phase 2 N=42 Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Ganglioneuroblastoma · High Risk Neuroblastoma
Primary: Percentage of Participants With Unacceptable Toxicity — 0.0 percentage of patients
N/A N=41 Silver Diamine Fluoride Pilot Study (SDF)
Dental Caries
Primary: Assessment of Radiographic Change in Dental Cavity — 9; 11; 3; 2 Participants
N/A N=384 Lung Ultrasound Implementation in the Management of Patients Hospitalized With COVID-19
Covid19
Primary: Hospitalists Who Adopt Lung Ultrasound — 4 Participants
N/A N=167 Study of Hypofractionated Proton Beam Radiation Therapy for Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Late Treatment-Related Toxicity Greater Than or Equal to Grade 3, CTCAE Version 4.0 — 1 Participants
Phase 1 N=12 A Study to Evaluate the Pharmacokinetics and Safety of Brivaracetam in Healthy Chinese Subjects
Healthy Participants
Primary: Plasma Concentration of BRV and Its Metabolites (Ucb-42145, Ucb-100406-1, ucb107092-1) After Single Dose — NA; 1039; 2610; 2725 nanograms/milliliter (ng/mL)
N/A N=52 Hybrid L24 New Enrollment Post Approval Study
High Frequency Sensorineural Hearing Loss
Primary: Change in Consonant-Nucleus-Consonant (CNC) Word Recognition in Quiet for the Two Listening Conditions: Implant Ear Alone and When Using Both Ears Together From…
N/A N=30 Adaptation of Ca-HELP Intervention in Rural Geriatric Cancer Patient Population
Pain
Primary: Feasibility (Aim 2), as Measured by Number of Subjects Accrued to the Study — 30 Participants
Phase 2 N=12 Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder
Body Dysmorphic Disorders
Primary: Body Dysmorphic Disorder Modification of the Yale-Brown Obsessive Compulsive Disorder Scale — 18.42 score on a scale — p=<0.001
Phase 2 N=557 A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
Melanoma · Renal Cell Carcinoma · Non Small Cell Lung Cancer
Primary: Part 1 Dose Escalation: Incidence of Dose-limiting Toxicity (DLT) During the DLT Evaluation Window — 0; 0; 0; 0 Participants
N/A N=41 Examining the Effects of Neural Stimulation on Inhibitory Control and Cigarette Smoking
Tobacco Use Disorder
Primary: The Effects of cTBS vs. iTBS TMS Applied to the r.IFG on Change in Behavioral Inhibition Between Baseline and 1 Hour Post Treatment. — -3.078; 3.778 Percentage of…
Phase 2 N=105 Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting · Multiple Sclerosis, Secondary Progressive · Multiple Sclerosis, Primary Progressive
Primary: Change in Cognitive Function as Assessed by the Symbol Digit Modalities Test (SDMT) — 0.145; 0.207; 0.163 score on a scale
Phase 2 N=18 Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia
Severe Aplastic Anemia · Bone Marrow Failure Syndromes
Primary: Is This Type of Transplantation for Severe Aplastic Anemia Feasible and Safe? — 18 Participants